Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ING Groep NV (ING) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

ING Groep NVTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

ING Groep NV vs Inovio Pharmaceuticals Inc — how do they compare? ING Groep NV trades at $35.57 (market cap $101.22B), while Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M). The key difference: ING Groep NV is far larger — about 1288.6× Inovio Pharmaceuticals Inc's market cap, and ING Groep NV pays a 3.73% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

INGINO
Market Cap
$101.22B$78.55M
Sector
FinancialsHealth
52-Week High
$35.92$2.87
52-Week Low
$23.66$0.66
Dividend Yield
3.73%
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ING Groep NV

ING trades at $35.24, down 1.23% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.79, and raised its full-year revenue guidance. Analyst consensus is strongly positive with 62.5% buy ratings. Recent news highlights strategic acquisitions and a dividend payment scheduled for August 2026.

The outlook for ING is favorable, supported by earnings momentum and upward guidance revisions. Key opportunities include growth in net interest income and fee-based revenue. Risks involve persistent negative operating cash flows and sensitivity to European economic conditions. The stock presents a value proposition with a P/E of 13.24, though cash flow trends warrant monitoring.

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

Returns comparison

Trailing returns across standard periods

About ING Groep NV

The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.

Read more on ING

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO